Document Detail


Melanoma prognostics and personalized therapeutics at a crossroad.
MedLine Citation:
PMID:  23318787     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Melanoma has recently emerged as a poster child for targeted therapies and immunotherapies, with game-changing BRAF and immune checkpoint inhibitors now in clinical trials and with approved clinical indications. One highly anticipated use of novel therapeutic agents is in the adjuvant setting. Adjuvant BRAF and/or immune checkpoint inhibition may positively affect the survival of melanoma patients diagnosed at earlier stages but still at high risk for postsurgical relapses. BRAF V600 mutations and, potentially, melanoma-associated immunity are predictive biomarkers for responses to these novel therapies. Emerging evidence points to these predictive biomarkers doubling as prognostic biomarkers for high-risk stage III patients, promising to help stratify these patients for the application of novel adjuvant therapies.
Authors:
Roger S Lo
Related Documents :
23376707 - Obesity is associated with worse outcomes in patients with t1 high grade urothelial car...
24100087 - Polymorphisms of folate metabolism-related genes and survival of patients with colorect...
23564257 - Sex is not an independent risk factor for survival in differentiated thyroid cancer.
24423367 - Tumor associated macrophages polarization dictates the efficacy of bcg instillation in ...
20432747 - Cd20 positive childhood b-non hodgkin lymphoma (b-nhl): morphology, immunophenotype and...
10516747 - A phase ii trial of induction and consolidation therapy of acute myeloid leukemia with ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of investigative dermatology     Volume:  133     ISSN:  1523-1747     ISO Abbreviation:  J. Invest. Dermatol.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0426720     Medline TA:  J Invest Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  292-5     Citation Subset:  IM    
Affiliation:
1] Department of Medicine, Division of Dermatology, David Geffen School of Medicine, University of California, Jonsson Comprehensive Cancer Center, Los Angeles, California, USA [2] Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Jonsson Comprehensive Cancer Center, Los Angeles, California, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Dacarbazine in melanoma: from a chemotherapeutic drug to an immunomodulating agent.
Next Document:  Nitroarachidonic acid prevents NADPH oxidase assembly and superoxide radical production in activated...